Ticagrelor Tablet
Product Images NDC 11788-157

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 11788-157). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aiping Pharmaceutical, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60 mg (60s)

60 mg (60s)
Ticagrelor Tablets label for 60 mg dosage strength. The label states "Rx Only" and indicates the package contains 60 tablets. It includes manufacturer information for AiPing Pharmaceutical, Inc, and storage instructions to keep at 25°C (77°F), with permitted excursions. The label also mentions dispensing the Medication Guide to each patient and provides a website for the guide. Barcode and revision date 03/2026 are shown.*
FDA Label Image

90 mg (100s)

90 mg (100s)
Label for Ticagrelor Tablets 90 mg oral tablets by AiPing Pharmaceutical, Inc. The label indicates a package quantity of 100 tablets and includes storage instructions, dosing warnings, and a barcode. It specifies the medication guide URL and expiry date of 03/2026.*
FDA Label Image

90 mg (60s)

90 mg (60s)
Ticagrelor Tablets 90 mg oral tablets packaging label showing the product name, strength, quantity of 60 tablets, and labeler AiPing Pharmaceutical, Inc. The label includes dosage information, storage instructions, an NDC code 11788-158-60, and a barcode.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of ticagrelor depicted as a two-dimensional molecular diagram showing its atomic connectivity and arrangement.*
FDA Label Image

Figure 15 (Figure 15)

Figure 15 (Figure 15)
A line graph showing the cumulative percentage of first occurrences of cardiovascular death, myocardial infarction, or stroke over time (months from randomization) comparing Ticagrelor with placebo. The x-axis represents months from randomization up to 54 months, and the y-axis shows cumulative percentage from 0 to 14%. Solid line represents Ticagrelor data, dashed line represents placebo. The chart includes numbers at risk for each group over time.*
FDA Label Image

Figure 16 (Figure 16)

Figure 16 (Figure 16)
A subgroup analysis forest plot from the THEMIS study comparing ticagrelor versus placebo across various patient characteristics including age, sex, race, body mass index, geographic region, aspirin dose, HbA1c, kidney function, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and diabetes duration. The plot shows hazard ratios and confidence intervals, indicating comparative effectiveness between ticagrelor and placebo.*
FDA Label Image

Figure 17 (Figure 17)

Figure 17 (Figure 17)
A Kaplan-Meier curve chart depicting the time to first occurrence of stroke or death comparing Ticagrelor 90 mg twice daily with placebo over about 34 days. The cumulative percentage on the y-axis rises over days from randomization on the x-axis, showing fewer events in the Ticagrelor group compared to placebo.*
FDA Label Image

Figure 18 (Figure 18)

Figure 18 (Figure 18)
Figure 18 is a forest plot showing subgroup analyses of ticagrelor 90 mg versus placebo from the THALES study. The chart presents hazard ratios with 95% confidence intervals across patient characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis, and medical history variables, comparing ticagrelor to placebo outcomes.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A cumulative percentage line graph titled 'Time course of GUSTO severe bleeding events' comparing Ticagrelor 90 mg twice daily versus placebo. The x-axis indicates days from randomization (0 to 34), and the y-axis shows cumulative percentage (0 to 1.0). The solid line represents Ticagrelor, showing higher cumulative events over time compared to the dashed placebo line. A risk table below shows patient counts at various time points for both groups.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
Line graph showing mean inhibition of platelet aggregation over 8 hours following single oral doses of placebo, 180 mg ticagrelor, and 600 mg clopidogrel. The y-axis represents IPA percentage induced by 20μM ADP, and the x-axis shows time in hours. Ticagrelor exhibits the highest inhibition followed by clopidogrel, with placebo showing minimal effect.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A line graph titled 'Mean inhibition of platelet aggregation (IPA) following 6 weeks on placebo, ticagrelor 90 mg twice daily, or clopidogrel 75 mg daily.' The graph plots IPA (%) induced by 20uM ADP over 10 days for three groups: ticagrelor, clopidogrel, and placebo. Ticagrelor shows the highest IPA initially, decreasing over time, followed by clopidogrel, with placebo showing minimal IPA. An inset graph shows a detailed IPA (%) response over 48 hours for the same groups.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
Figure 8 displays a graph illustrating the effect of various co-administered drugs on the pharmacokinetics of ticagrelor. The chart shows changes relative to reference in ticagrelor and AR-C124910XX levels, measured as Cmax and AUC, for interacting drugs such as ketoconazole, diltiazem, rifampin, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl. Recommendations for dose adjustments or avoidance of use are noted alongside.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
A pharmacokinetic interaction chart illustrating the impact of ticagrelor tablets at various doses on co-administered drugs. The chart plots mean effect and 90% confidence intervals for several interacting drugs, including simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine, comparing change relative to drug alone. Recommendations for dose adjustments are listed alongside each drug.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
A line graph titled 'Time to first TIMI Major bleeding event (THEMIS)' showing cumulative percentage (%) over months from randomization, comparing Ticagrelor (solid line) and placebo (dashed line). The graph includes event numbers and sample sizes (N) for both groups over a 54-month period.*
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
A figure showing the impact of intrinsic factors on the pharmacokinetics of ticagrelor. It presents mean effect and 90% confidence intervals for ticagrelor and AR-C124910XXC regarding Cmax and AUC across various intrinsic factors like age, gender, ethnicity, renal and hepatic impairment. Recommendations for no dose adjustment are noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.